Rice Hall James & Associates LLC Invests $2.15 Million in Omnicell, Inc. $OMCL

Rice Hall James & Associates LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 51,789 shares of the company’s stock, valued at approximately $2,150,000. Rice Hall James & Associates LLC owned about 0.11% of Omnicell at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in OMCL. Wellington Management Group LLP increased its stake in shares of Omnicell by 156.4% in the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after purchasing an additional 1,265,818 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Omnicell during the 3rd quarter worth $25,625,000. First Light Asset Management LLC acquired a new stake in Omnicell in the first quarter valued at about $16,351,000. Boston Partners acquired a new stake in Omnicell in the fourth quarter valued at about $20,805,000. Finally, WCM Investment Management LLC bought a new position in Omnicell in the first quarter valued at about $9,783,000. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on OMCL shares. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Wells Fargo & Company lowered their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Craig Hallum reissued a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Piper Sandler restated an “overweight” rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Finally, Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Performance

NASDAQ:OMCL opened at $35.97 on Wednesday. The stock’s 50-day moving average is $40.50 and its 200-day moving average is $39.89. Omnicell, Inc. has a 1-year low of $29.06 and a 1-year high of $55.00. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.64 billion, a P/E ratio of 42.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. During the same quarter last year, the business earned $0.45 EPS. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.3 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.